Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.

Key Points Merck aims to boost its business by buying Verona Pharma for $10 billion.Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.With the stock valued at ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Raleigh’s Verona Pharma acquired by Merck for $10 billion as maker of COPD treatment Ohtuvayre merges with pharmaceutical company with growing Durham, NC footprint ...